← Back to list
Suprachoroidal Delivery of Pharmacological Agents
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
This policy was last reviewed 06/24/2024 with no changes. Suprachoroidal delivery of a pharmacologic agent is considered investigational. Delivery of pharmacological agents to the suprachoroidal space is being investigated for treatment of posterior eye segment diseases. Investigational codes listed are CPT 67516 (new 01/01/2024), CPT 0465T (deleted 12/31/2023) and CPT 67299 (unlisted procedure, posterior segment).
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
Action · 2 steps
01Billing team: Suprachoroidal delivery of a pharmacologic agent is investigational and therefore not considered medically necessary, and BCBSMS makes no payment for services not documented to be Medically Necessary.
02Before billing, check whether the member is in the Federal Employee Program (FEP), since FEP may dictate that FDA-approved devices, drugs or biologics may not be considered investigational and may be assessed only on the basis of medical necessity.
Codes mentioned
6751667299
Original notice
Suprachoroidal Delivery of Pharmacological Agents
bcbsms.com · Always check the source before changing claims.
Related changes
See all Blue Cross & Blue Shield of Mississippi changes →Gene Therapy for Inherited Retinal DystrophyMediumEffective Jan 1, 2025 · Medical PolicyTranspupillary Thermotherapy for Treatment of Choroidal Neovascular ConditionsMediumNo effective date · Medical PolicyIntraocular Radiotherapy for Age-Related Macular DegenerationMediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list